SES
23.4.2020 08:52:11 CEST | Business Wire | Press release
SES announced today that the number of global TV households it reaches directly or indirectly via satellite has increased by 12 million to 367 million in 2019. Findings from the company’s annual Satellite Monitor market research validates, once again, SES’s position as the world’s leading video content distributor via satellite and shows the important role that satellite continues to play in reaching the largest possible audience globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200422006137/en/
Much of the increase in the 12 million TV households is attributed to the leading infrastructure of TV reception – satellite and cable – which grew by 9 million in 2019 to 153 million and 149 million homes respectively. Internet Protocol TV (IPTV) and terrestrial TV grew by a combined 3 million to 43 million and 21 million homes.
The Satellite Monitor study also showed that SES’s technical reach has increased across several continents, including Europe, Africa, Asia-Pacific (APAC), and Latin America (LATAM). Europe continues to be the strongest market for SES, with 168 million total households served by the SES fleet, up by 1 million from 2018, followed by North America at 69 million.
In LATAM, SES has captured an audience of 42 million households, a significant increase from the 34 million households reported in 2018, thanks in part to the launch of a new satellite – SES 14 – which is boosting cable and IPTV growth in the region. This year also marked the first year that SES collected results from Indonesia and the Philippines. In total, SES serves 39 million APAC households with Direct-to-Home (DTH) feeds. The research also found that SES delivers digital television to 13 million households in the Middle East and 35 million homes in Africa. Altogether, SES has observed a combined growth of almost 5 million households across APAC and Africa.
SES’s TV market research sheds light on several key trends behind the relevance of satellite broadcasting, including the transition from analog to digital TV and the rise of HD broadcast. End consumers in Ghana and Nigeria are choosing satellite TV for its better value proposition and free-to-air offerings, rather than purchasing new hardware and switching to digital terrestrial TV. The Satellite Monitor study also revealed that HD broadcast has been on the rise in Europe, with 167 million TV households, an increase of 5 million from 2018. Satellite remains the preferred choice of infrastructure when it comes to HD content broadcasting, underscoring the key value proposition of satellite broadcasting as a reliable and cost-effective video delivery to large audiences.
“Broadcasters and TV platform operators need robust and reliable data before they make the decision to enter new markets. For more than 25 years, SES has been the only satellite-based solutions provider in the world to regularly and extensively monitor the industry in specific countries and identify key trends for our customers to help them succeed in their business and expand their reach,” said Ferdinand Kayser, CEO at SES Video. “The results of our annual Satellite Monitor market research demonstrate that satellite continues to be the most optimal infrastructure to deliver high picture quality, and that despite changing consumption habits, people still strongly rely on linear TV and complement it with OTT content.”
Introduced in 1994, SES’s annual Satellite Monitor research reveals the detailed technical reach of SES and valuable insights into the video market and trends worldwide. It is seen as an important tool for SES’s customers, the leading broadcasters and content owners.
Follow us on:
Social Media
Blog
Media Library
About SES
SES has a bold vision to deliver amazing experiences everywhere on earth by distributing the highest quality video content and providing seamless connectivity around the world. As the leader in global content connectivity solutions, SES operates the world’s only multi-orbit constellation of satellites with the unique combination of global coverage and high performance, including the commercially-proven, low-latency Medium Earth Orbit O3b system. By leveraging a vast and intelligent, cloud-enabled network, SES is able to deliver high-quality connectivity solutions anywhere on land, at sea or in the air, and is a trusted partner to the world’s leading telecommunications companies, mobile network operators, governments, connectivity and cloud service providers, broadcasters, video platform operators and content owners. SES’s video network carries over 8,300 channels and has an unparalleled reach of 367 million households, delivering managed media services for both linear and non-linear content. The company is listed on Paris and Luxembourg stock exchanges (Ticker: SESG). Further information is available at: www.ses.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200422006137/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom